516-79-0

Usage

Uses

Used in Pharmaceutical Industry:
22,23-Dihydroergosterol, non-irradiated is used as an active pharmaceutical ingredient for the development of drugs targeting various health conditions. Its unique chemical structure allows it to interact with specific biological targets, making it a promising candidate for drug discovery and development.
Used in Nutraceutical Industry:
In the nutraceutical industry, 22,23-dihydroergosterol, non-irradiated is used as a dietary supplement due to its potential health benefits. As a phytosterol, it may help in maintaining healthy cholesterol levels and supporting overall cardiovascular health.
Used in Cosmetic Industry:
22,23-Dihydroergosterol, non-irradiated is used as an ingredient in the cosmetic industry for its potential anti-aging and skin health benefits. Its chemical properties may contribute to improved skin hydration, elasticity, and overall appearance.
Used in Agricultural Industry:
In agriculture, 22,23-dihydroergosterol, non-irradiated can be used as a natural additive to enhance the nutritional value of animal feed, promoting better health and productivity in livestock.
Used in Research and Development:
22,23-Dihydroergosterol, non-irradiated is also utilized in research and development for studying its potential applications in various fields, including pharmacology, biotechnology, and material science. Its unique chemical structure makes it an interesting subject for further exploration and innovation.

InChI:InChI=1/C28H46O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h9-10,18-20,22,24-26,29H,7-8,11-17H2,1-6H3

Upstream product

• 2579-14-8 ergostadien-(5,7)-yl-(3β)-acetate 
• 20304-51-2 (24S)-ergosta-5,7-diene-3β-ol 
• 71-43-2 benzene 
• 248580-58-7 3β-tert-butyldimethylsilyloxyergosta-5,7,22-triene-5α,8α-(1,4-dioxo-1,2,3,4-tetrahydrophthalazine-2,3-diyl)ergosta-6,22-diene 

Downstream Products

• 516-78-9 (3β,5α)-ergost-7-en-3-ol 
• 516-79-0 lumistadien-(5,7)-ol-(3β) 
• 511-28-4 2,2-dihydroergocalciferol 
• 6034-33-9 O-benzoyl-fungisterol 
• 6034-34-0 O-(3.5-dinitro-benzoyl)-fungisterol 
• 632-32-6 (3β,5α)-ergost-8(14)-en-3-ol 
• 16744-89-1 2-methylhex-5-en-2-ol 
• 42152-47-6 7-methyl-1,6-octadiene 
• 120176-30-9 suprasterol4 
• 37706-52-8 previtamin D₄ 
• 511-28-4 vitamin D₄ 
• 122276-71-5 toxisterol D 
• 122293-10-1 toxisterol F 
• 37706-52-8 previtamin D₄ 

Relevant academic research and scientific papers

Effect of sterol side chain on ion channel formation by amphotericin b in lipid bilayers

Amphotericin B (AmB) is one of the most efficient antimycotic drugs used in clinical practice. AmB interacts with membrane sterols increasing permeability of fungal membranes; however, it is still unclear how AmB selectively recognizes the fungal sterol, ergosterol (Erg), over other sterols in cell membranes. In this study, we investigated the effect of an Erg side chain on AmB activity by testing a series of Erg analogues that shared the same alicyclic structure as Erg but varied in the side chain structure by using the K+ influx assay. The results clearly showed that the sterol side chain is essential for AmB selectivity toward Erg and for the activity of AmB-sterol ion channels. In agreement with our previous findings showing the direct interaction between the drug and Erg, these data suggested that AmB directly recognizes the sterol side chain structure, consequently promoting the formation of ion channels by AmB. Furthermore, the C24 methyl group and Δ22 double bond in the side chain of Erg are equally important for the interaction with AmB. Conformational analysis revealed that the C24 methyl group contributes to the interaction by increasing the van der Waals (VDW) contact area of the side chain, while the Δ22 double bond restricts the side chain conformation to maximize the VDW contact with the rigid AmB aglycone. This study provides direct experimental evidence of the mechanism of AmB selectivity toward fungal Erg.

Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof

The disclosure is of methods of treating various skin disorders, including skin cancer, with compounds of novel 1α-hydroxy vitamin D4 and novel analogues, thereof, including 1,25 dihydroxy vitamin D4 and 1,24 dihydroxy vitamin D4. Novel 1α-hydroxy vitamin D4 compounds and compounds of novel analogues suitable for use in the treatment of such disorders are also disclosed herein.

Method of inhibiting the hyperproliferation of malignant cells

1α-hydroxy vitamin D4 and analogues, preferably 1,24 dihydroxy vitamin D4, which are useful as active compounds of pharmaceutical compositions for the inhibition of hyperproliferative activity of malignant cells.

1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions

Disclosed are new 1α-hydroxy vitamin D7 of formula (I) and 1α-hydroxy vitamin D4 of formula (II) which are useful as active ingredients of pharmaceutical compositions for the treatment of osteoporosis. Those new compounds are synthesized starting from (22E)-5α,8α-(4-phenyl-1,2-urazolo)-6,22-ergostadien-3β-ol 3β-tert-butyl-dimethylsilyl ether and through ten process steps.